Evidence map›Paper›PMID 41080598›Full record

ArticleFrontiers in immunology2025

SPP1 as a biomarker for idiopathic membranous nephropathy progression and its regulatory role in inflammation and fibrosis.

Shuting Pang, Rongbin Zhou, Zige Liu, Boji Xie, Fugang Liu, Bingmei Feng, Xuesong Chen, Liangping Ruan, Hong Chen, Yuli Xie and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shuting Pang *Department of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Rongbin Zhou *Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, University Engineering Research Center of Digital Medicine and Healthcare, Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Zige Liu *Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, University Engineering Research Center of Digital Medicine and Healthcare, Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Boji XieDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Fugang LiuDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Bingmei FengDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Xuesong ChenDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Liangping RuanDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Hong ChenDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Yuli XieDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Qiuyan TanDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Binran ZhaoDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Shanshan LiDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Chao XueDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Rirong YangDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.
Wei LiDepartment of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome in middle-aged and elderly populations. Early intervention can delay disease progression and improve patient outcomes. This study aims to identify urinary biomarkers for IMN and investigate their association with disease progression, offering new insights for precise diagnosis and treatment. Methods: This study began with RNA sequencing of three urine sample types (first-void morning urine, second-void morning urine, and random urine), combined with single-cell RNA sequencing of renal tissues. Bioinformatics analyses-including differential gene expression screening, machine learning, and molecular function annotation-were employed to identify potential IMN biomarkers. Furthermore, we established both a siRNA-mediated gene silencing model and a lentivirus transfection-mediated gene overexpression model in HK-2 cells. Subsequently, we investigated the functional mechanisms of the candidate biomarkers through qRT-PCR, Western blot, immunohistochemistry, and immunofluorescence assays. Results: SPP1 was identified as a promising biomarker for IMN, demonstrating a critical role in promoting fibrosis and inflammatory responses associated with the disease. These findings suggest its potential as a novel therapeutic target for IMN intervention.

Indexed as

Glomerulonephritis, MembranousInflammationOsteopontinAdultBiomarkersCell LineDisease ProgressionFemaleFibrosisHumansKidneyMaleMiddle AgedBiomarkersOsteopontinSPP1 protein, humanfibrosisidiopathic membranous nephropathyinflammationproximal tubular cellsSPP1

Identifiers

PMID41080598
PMCPMC12510867

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.